findmyKOL

Guillermo Garcia-Manero, MD

Enriched profile

Chair Ad Interim, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center · The University of Texas MD Anderson Cancer Center

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Houston, TX · South Central · United StatesSpecialtyMedical OncologyFocusAcute Myeloid Leukemia Research+4
Active KOLEmergingfindmyKOL type: EliteLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding2004–2008

Guillermo Garcia-Manero is Chair Ad Interim, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center at The University of Texas MD Anderson Cancer Center. OpenAlex indexes 2,993 publications with 90,546 citations (h-index 150); ClinicalTrials.gov lists 25 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Medical Oncology profiles in the findmyKOL directory. Clarivate lists Guillermo Garcia-Manero as a Highly Cited Researcher (Clinical Medicine, 2015-2016, 2018-2020, 2024).

Data verified 14 Aug 2026

Overview

Updated 14 Oct 2026

Guillermo Garcia-Manero, M.D., is Chair Ad Interim, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center. The public record shows 2,993 publications with 90,546 citations (h-index 150), centered on Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Myeloproliferative Neoplasms: Diagnosis and Treatment. It also documents an investigator role on 25 registered clinical trials, industry payments reported by 30 companies, 3 NIH-funded awards (2004–2008).

  • Most recent indexed publication: 2026 · American journal of hematology
  • Top research focus: Acute Myeloid Leukemia Research
  • 25 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 30 companies

Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Leukemia (AML/ALL/CML/CLL)25 trialsMDS / MPN14 trialsLeukemia, Myeloid, Acute8 trialsPrecursor Cell Lymphoblastic Leukemia-Lymphoma2 trialsLeukemia, Promyelocytic, Acute1 trialLeukemia, Lymphoid1 trialMyeloproliferative Disorders1 trial

Research focus

OpenAlex concept fingerprint
Acute Myeloid Leukemia ResearchChronic Myeloid Leukemia TreatmentsMyeloproliferative Neoplasms: Diagnosis and TreatmentAcute Lymphoblastic Leukemia researchChronic Lymphocytic Leukemia Research

Drugs & molecules

across trials, industry payments and publications
Venclextageneric · VenetoclaxClinical trials3Industry payments4Publications33Onureggeneric · AzacitidineClinical trials10Industry payments2Publications18DecitabineClinical trials3Industry payments1Publications9Reblozylgeneric · LuspaterceptClinical trials—Industry payments9Publications4CytarabineClinical trials3Industry payments—Publications9Tibsovogeneric · IvosidenibClinical trials—Industry payments5Publications1IdarubicinClinical trials2Industry payments—Publications3NivolumabClinical trials2Industry payments—Publications3VorinostatClinical trials3Industry payments—Publications2IpilimumabClinical trials1Industry payments—Publications2PracinostatClinical trials2Industry payments—Publications1CanakinumabClinical trials1Industry payments—Publications1

Works with

trial sponsors and companies reporting payments
Celgene CorporationClinical trials—Industry payments55E.R. Squibb & Sons, L.L.C.Clinical trials—Industry payments28Taiho Oncology, Inc.Clinical trials—Industry payments22M.D. Anderson Cancer CenterClinical trials20Industry payments—Geron CorporationClinical trials—Industry payments13Novartis Pharmaceuticals CorporationClinical trials—Industry payments13GlaxoSmithKline, LLC.Clinical trials—Industry payments11Gilead Sciences, Inc.Clinical trials—Industry payments7AstraZeneca Pharmaceuticals LPClinical trials—Industry payments5Hikma Pharmaceuticals USAClinical trials—Industry payments5Servier Pharmaceuticals LLCClinical trials—Industry payments5Abbvie Inc.Clinical trials—Industry payments4Dr.Reddy's Laboratories,Inc.Clinical trials—Industry payments4Regeneron Pharmaceuticals, Inc.Clinical trials—Industry payments4Helsinn Healthcare SAClinical trials2Industry payments—Otsuka Pharmaceutical Co., Ltd.Clinical trials—Industry payments2Sumitomo Pharma America, Inc.Clinical trials—Industry payments2Takeda Pharmaceuticals U.S.A., Inc.Clinical trials—Industry payments2AstraZeneca UK LimitedClinical trials—Industry payments1Chiesi USA, Inc.Clinical trials—Industry payments1Chordia Therapeutics, Inc.Clinical trials1Industry payments—Daiichi Sankyo Inc.Clinical trials—Industry payments1Epizyme, Inc.Clinical trials1Industry payments—Genentech USA, Inc.Clinical trials—Industry payments1Ipsen Biopharmaceuticals, IncClinical trials—Industry payments1Ipsen InnovationClinical trials—Industry payments1Janssen Global Services, LLCClinical trials—Industry payments1Merck Sharp & Dohme LLCClinical trials—Industry payments1National Cancer Institute (NCI)Clinical trials1Industry payments—Sanofi-Aventis U.S. LLCClinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
2,993publications

Distinct works indexed by OpenAlex, matched via ORCID; 190 in PubMed.

90,546citations

Total citations across indexed works.

150h-index

Hirsch index (OpenAlex). i10-index 1,037.

Clinical & industry

trials, payments and federal funding
25clinical trials

Investigator role on registered studies.

View trials ↓
30companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
3NIH grants · 2004–2008

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 14 Oct 2026

Listed as an investigator on 25 registered studies on ClinicalTrials.gov. The most recent:

All 25 trial records: search, sort and filter.Explore →

Industry payments

Updated 14 Oct 2026

30 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

All 55 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    59.7%
    BCL-2 Inhibitor59.7%
    Venclexta100%
    Part D≥12 patients

  • Anti-infectives

    40.3%
    Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor22.4%
    Valacyclovir100%
    Part D<11 patients
    Fluoroquinolone Antibacterial17.9%
    Levofloxacin100%
    Part D<11 patients
Where care is delivered (Part B)94.2% facility · 5.8% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 14 Oct 2026

3 NIH research awards on record, funded 2004–2008 per NIH RePORTER. The latest:

All 6 award records: search, sort and filter.Explore →

Publications

Updated 14 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

All 190 publications: search, sort and filter.Explore →

Most-cited works

by citation count (OpenAlex)
  1. 01
    Revised International Prognostic Scoring System for Myelodysplastic Syndromes
    3,145 citations2012
    doi.org ↗
  2. 02
    Clinical Effect of Point Mutations in Myelodysplastic Syndromes
    1,629 citations2011
    doi.org ↗
  3. 03
    Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies
    817 citations2003
    doi.org ↗
  4. 04
    Acute myeloid leukemia: current progress and future directions
    761 citations2021
    doi.org ↗
  5. 05
    Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia
    718 citations2012
    doi.org ↗
All 2,993 cited works: search, sort and filter.Explore →

Network

Updated 14 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Hagop M. Kantarjian1947Farhad Ravandi1460Elias Jabbour1242Tapan M. Kadia1236Jörge E. Cortes1011Gautam Borthakur1006Courtney D. DiNardo928Naval Daver886Naveen Pemmaraju680Marina Konopleva676Koji Sasaki625Nicholas J. Short608Guillermo Montalban‐Bravo598Sherry Pierce496Koichi Takahashi466Susan O’Brien411Nitin Jain409Srđan Verstovšek356Sanam Loghavi349Michael Andreeff345Rashmi Kanagal‐Shamanna334Yesid Alvarado326Kelly S. Chien325Stefan Faderl322William G. Wierda318Ghayas C. Issa316Zeev Estrov295Keyur P. Patel276Musa Yılmaz271Carlos E. Bueso‐Ramos260Alessandra Ferrajoli239Steven M. Kornblau229Deborah A. Thomas229Rami S. Komrokji208Naval Daver199Danielle Hammond199Hui Yang182Mikkael A. Sekeres181Guilin Tang175Prithviraj Bose173

Online presence

Updated 14 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/guillermo-garcia-manero-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
  • LinkedIn

    linkedin.com/in/guillermo-garcia-manero-md-99420475

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
  • ResearchGate

    researchgate.net/scientific-contributions/Guillermo-Garcia-Manero-2143705602

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
  • ResearchGate

    researchgate.net/scientific-contributions/Guillermo-Garcia-Manero-2165165227

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
  • ResearchGate

    researchgate.net/scientific-contributions/Guillermo-Garcia-Manero-2165190381

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
  • X / Twitter

    x.com/garciamanero

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com ↗

Mentions by others

where others cite or feature them
  • Instagram

    instagram.com/aamdsif/reel/CyDZdbps9oh

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗
  • X / Twitter

    twitter.com/leukemiamda

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →twitter.com ↗
  • LinkedIn

    linkedin.com/posts/mdandersoncancercenter_our-dr-guillermo-garcia-manero-and-md-anderson-activity-7102289362859544576-vywT

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
  • Spotify

    bloodcancerstoday.com/podcast/dr-garcia-manero-on-the-data-behind-the-luspatercept-approval

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bloodcancerstoday.com ↗
  • YouTube

    youtube.com/playlist

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
  • YouTube

    YouTube video: "Guillermo Garcia-Manero, MD, on a 'Total Approach' to MDS", SOHO congress interview

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
  • YouTube

    YouTube video: "Guillermo Garcia-Manero, MD, on the Phase III COMMANDS Trial" (published June 2023)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
  • YouTube

    YouTube playlist: "MDS Roundtable Moderated by Guillermo Garcia-Manero, MD" (Blood Cancers Today Associate Editor role)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
  • Bloodcancerstoday.com

    Blood Cancers Today podcast: "Dr. Garcia-Manero on the Data Behind the Luspatercept Approval" and related episodes (author/contributor page)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bloodcancerstoday.com ↗
  • Instagram

    Instagram (CURE Today, org account): post at #ASCO24 featuring Dr. Guillermo Garcia-Manero

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →instagram.com ↗
  • Instagram

    Instagram (AAMDSIF, org account): reel of Dr. Garcia-Manero receiving AAMDSIF Leadership in Science Award, March 2024

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →instagram.com ↗
  • LinkedIn

    LinkedIn (MD Anderson Cancer Center official company account): post quoting "our Dr. Guillermo Garcia-Manero" on the Phase III COMMANDS study/luspatercept FDA approval

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
  • X / Twitter

    X/Twitter (MD Anderson Leukemia departmental account, @leukemiamda): departmental account for the section he chairs ad interim; topical overlap confirmed, direct tag of KOL not independently confirmed

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →twitter.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 14 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Board Certified

    Medical Oncology, 1999

    2016
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →sohoonline.org ↗
  • Active Medical License

    State of Texas, since 2000

    2000
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →faculty.mdanderson.org ↗
  • Clinical Fellowship

    Hematology and Medical Oncology, Thomas Jefferson University Hospital, Cardeza Foundation and Kimmel Cancer Center, Philadelphia, PA, 1996-1999

    1999
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Board Eligible

    Hematology

    1999
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →sohoonline.org ↗
  • Clinical Internship and Residency

    Internal Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, 1993-1996

    1996
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Board Certified

    Internal Medicine

    1996
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →sohoonline.org ↗
  • M.D. (Medical Doctor)

    University of Zaragoza School of Medicine, Zaragoza, Spain

    1991
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗

Editorial & leadership roles

journal and society appointments
  • President 2023-2024

    Society of Hematologic Oncology (SOHO); Chair, 2024 SOHO Annual Meeting

    2024
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →sohoonline.org ↗
  • Chair

    Faculty Senate, The University of Texas MD Anderson Cancer Center, 2020-2021

    2022
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Fellowship Program Director

    Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 2019-present

    2019
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Dr. Kenneth B. McCredie Chair in Clinical Leukemia Research

    The University of Texas MD Anderson Cancer Center, 2015-present (endowed position)

    2015
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →sohoonline.org ↗
  • Leader

    MDS/AML Moon Shot Program, The University of Texas MD Anderson Cancer Center

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →sohoonline.org ↗
  • Chief

    Section of Myelodysplastic Syndromes, Department of Leukemia, The University of Texas MD Anderson Cancer Center

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →sohoonline.org ↗

Highly Cited Researcher

Clarivate's annual list, by award category and year
  • Clinical Medicine
    201520162018201920202024
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.